Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
| Autor: | Lavallée I, Julie Poirier, C. Che, Castaigne Jp, R. Gabathuler, M. Demeule, Richard Béliveau, Anthony Regina |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
medicine.medical_specialty biology business.industry Cancer medicine.disease Blood–brain barrier chemistry.chemical_compound ANG1005 Endocrinology medicine.anatomical_structure chemistry Paclitaxel Ovarian carcinoma Internal medicine Drug delivery biology.protein Cancer research Medicine Drug carrier business P-glycoprotein |
| Zdroj: | British Journal of Pharmacology. 155:185-197 |
| ISSN: | 0007-1188 |
| DOI: | 10.1038/bjp.2008.260 |
| Popis: | Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, Beliveau R, Castaigne JP. BACKGROUND AND PURPOSE : Paclitaxel is highly efficacious in the treatment of breast, head and neck, non-small cell lung cancers and ovarian carcinoma. For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier. We investigated the utilization of a new drug delivery system to increase brain delivery of (...) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|